Data from a new study published in NEJM Evidence shows promise for personalized use of short term ADT in men with predominantly intermediate-risk prostate cancer. The information validates the first-ever predictive AI biomarker of androgen deprivation therapy (ADT) benefit in prostate cancer.
Researchers with UC San Diego School of Medicine identified a potential new drug that improved liver fibrosis in patients with NASH by 27%.
Clinicians have a new standard for graft-versus-host disease (GVHD) prevention after allogeneic hematopoietic stem cell transplantation, according to results from a phase III study published in the New England Journal of Medicine. The new standard is more effective at preventing GVHD and came with less side effects, compared with the current gold standard.
A Vanderbilt University Medical Center-led study comparing the two types of laryngoscopes used in tracheal intubation of critically ill patients showed that the use of a video laryngoscope increased successful intubation on the first attempt, compared to the use of a direct laryngoscope, the standard approach for almost a century.
Mortality in patients with kidney failure has been found to be 23% lower among those treated with high dose haemodiafiltration compared to those treated with high flux haemodialysis, according to new research from the CONVINCE consortium led by University Medical Center Utrecht.
A study published in New England Journal of Medicine confirms that circulatory death donor hearts that are reanimated and perfused with blood outside of the body are as safe and effective to transplant as brain death donor hearts preserved using traditional cold storage. These findings suggest that using hearts donated after circulatory death (DCD) may have the potential to widen the donor pool helping more patients in need of life-saving heart transplants.
20221027104337.jpg&width=400&height=400)
A new study led by Yale Cancer Center shows improved rates of survival and reduced risk of recurrence in patients with non-small cell lung cancer taking osimertinib (TAGRISSO), a targeted therapy, following surgery. Non-small cell lung cancer (NSCLC), the most common type of lung cancer, tends to recur when diagnosed at advanced stages, which makes treatment challenging.
Three men who had heart failure caused by the build-up of sticky, toxic proteins are now free of symptoms after their condition spontaneously reversed in an unprecedented case described by a team at UCL and the Royal Free Hospital.
A study led by Duke Health physicians, appearing online June 8 in the New England Journal of Medicine, found that DCD hearts were equivalent to hearts procured through the current standard of care.
Patients with early relapsed or refractory large B-cell lymphoma had significantly improved overall survival when treated with the chimeric antigen receptor (CAR) T cell therapy axicabtagene ciloleucel (axi-cel) when compared to the current standard-of-care chemoimmunotherapy, according to results of the Phase III ZUMA-7 trial reported by researchers from The University of Texas MD Anderson Cancer Center.
In an international study co-led by UCLA, scientists have shown that a new targeted therapy drug can extend the amount of time people with a subtype of glioma are on treatment without their cancer worsening. The finding suggests a possible new treatment option for people with the slow-growing but deadly brain tumor.
Read about new melanoma treatment practices, how models provide information about a rare adrenal cancer, a potential oral medication for brain cancer, and clinical trials for cancer patients with HIV.
Breakthrough study addresses unmet need in the treatment of Crohn’s disease and helps patients into clinical and endoscopic remission
A global phase 3 clinical trial that included Ann & Robert H. Lurie Children’s Hospital of Chicago found that a year-long immunotherapy through a skin patch safely desensitized toddlers with peanut allergy, lowering the risk of a severe allergic reaction from accidental exposure. Results of this randomized, double-blind, placebo-controlled trial for children 1-3 years of age, funded by DBV Technologies, were published in the New England Journal of Medicine.
A targeted kinase inhibitor added to a two-drug immunotherapy combination slowed the progression of advanced kidney cancer in previously untreated patients, according to research published in The New England Journal of Medicine and led by an oncologist from Dana-Farber Cancer Institute.
As Medicare Advantage plans enroll more and more patients with serious illness, it is not clear how well the plans take care of these patients, Mount Sinai researchers say in a Perspective piece published today in the New England Journal of Medicine.
In a study of 17 people from five families, Johns Hopkins Medicine researchers say they found that ultra-lengthy DNA endcaps called telomeres fail to provide the longevity presumed for such people. Instead, people with long telomeres tend to develop a range of benign and cancerous tumors, as well as the age-related blood condition clonal hematopoiesis.
A new technique designed to allow surgeons to identify and remove residual tumor tissue during breast-conserving surgery showed promising results in a multi-center trial led by investigators from the Mass General Cancer Center, a member of Mass General Brigham.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right